Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9775551 | 0.97 | ATAD2 (0.32) | ATAD2POLBARAKR1B1 | |
| SCHEMBL6235409 | 0.72 | — | — | |
| SCHEMBL8908315 | 0.72 | POLB (0.34) | ATAD2POLBAR | |
| SCHEMBL23962148 | 0.72 | — | — | |
| SCHEMBL4621098 | 0.72 | — | — | |
| SCHEMBL542452 | 0.69 | LMNA (0.36) | — | |
| SCHEMBL1396164 | 0.69 | — | — | |
| SCHEMBL11250686 | 0.69 | POLB (0.32) | POLB | |
| SCHEMBL11702613 | 0.69 | POLB (0.31) | POLBAR | |
| SCHEMBL361226 | 0.69 | POLB (0.31) | POLBAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100792-B1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6624196-B2 | Particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, cardiovascular disorders | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6541521-B1 | Particularly gelatinase A, collagenase-3, and stromelysin-1 | WARNER-LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-6492422-B2 | GELATINASE A, COLLAGENASE-3, AND STROMELYSIN-1 INHIBITOR AND USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AROTIC ANEURYSM, HEART FAILURE, RESTENOSIS, PERIODONTAL DISEASE OR AUTOIMMUNE | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | disclosed |
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2002-10-31 | — | — | US | disclosed |
| US-6420408-B1 | MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, CARDIOVASCULAR DISORDERS, RESTENOSIS, PERIODONTAL DISEASE, AUTOIMMUNE OR INFLAMMATORY DISORDERS, ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, CEREBRAL AMYLOID ANGIOPATHY, | WARNER-LAMBERT COMPANY | 2002-07-16 | — | — | US | disclosed |
| EP-1100792-A1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006561-A1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161050-A1 | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP1, MMP8, MMP13 | ATAD2 1892/4885POLB 237/4885AR 3086/4885 |
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | MMP3, MMP12, MMP8 | ATAD2 1017/4885POLB 2408/4885AR 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.